Your browser doesn't support javascript.
loading
Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia.
Tamellini, E; Sorio, M; Andreini, A; Tecchio, C; Nadali, G; Bernardelli, A; Ferrarini, I; Crosera, L; Vatteroni, A; Simio, C; Benedetti, F; Krampera, M; Tanasi, I.
Afiliación
  • Tamellini E; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Sorio M; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Andreini A; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Tecchio C; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Nadali G; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Bernardelli A; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Ferrarini I; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Crosera L; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Vatteroni A; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Simio C; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Benedetti F; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
  • Krampera M; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Tanasi I; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
Blood Cell Ther ; 7(3): 75-78, 2024 Aug 25.
Article en En | MEDLINE | ID: mdl-39263622
ABSTRACT
Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Blood Cell Ther Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Blood Cell Ther Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Japón